iGATE says new data management tech will change R&D

By Natalie Morrison

- Last updated on GMT

Related tags Management

Pharmaceutical data managament: iGATE
iGATE says its new information management platform will provide a 70 per cent decrease in content management costs for the drug development process.

The tech – named the Research Accelorator (RA) – works from end-to-end, from data capture to management, product registrations, document and submission management, pharma co-vigilence risk management, reporting and analytics, and portfolio management.

The firm says because the entire trial is run under one do-it-all programme the process is less confusing and more streamlined, and hence less costly.

Speaking to Outsourcing-Pharma.com, associate VP Roy Devine said: “The Research Accelerator provides streamlined management of R&D data and can effectively replace the 300 or more applications currently utilized by most large pharma companies.

“It is also modular, so companies can derive benefits from the platform while leveraging their existing investments.”

Devine went on to brand the tech “transformative,” ​adding that it not only fits with the current changing trends in the industry, but also that it has the ability to change how R&D (research and development) will be conducted in the future.

“Changes in international regulations and an increasing focus on social media in the sector will prompt dramatic changes,”​ he said.

“The Research Accelerator platform and iGATE’s outcomes-based business model were strategically designed and implemented, respectively, with these developments in mind.”

As for new customers, the firm is open to any pharmaceutical company or CRO (contract research organisation) conducting clinical trials.

Devine added: “New customers do not need to completely overhaul their existing internal systems to gain benefit from the Research Accelerator as all that is necessary to gain value is to integrate the platform into their current operation over time.”

No win, no fee

Divine also that though the recent focus on “collaboration and mutual success”​ is novel now, it will no doubt be “the norm”​ in future, and said that iGATE’s outcome-based business model – which means payment is based on a specified result – reflects this.

“This ‘pay for results only’ formula enables customers to scale up and scale down based on business cycles, reduce technology risks, receive predictable results, benefit from a variable costs structure and eliminate management headaches from managing the outsourcing relationships,”​ he added.

Related news

Show more

Related products

show more

Unlock potential in buffer preparation

Unlock potential in buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 18-Sep-2023 | Infographic

Consider how the right partner can help you scale faster, mitigate risks, and optimize resources.

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 14-Aug-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Automated metadata management in clinical trials

Automated metadata management in clinical trials

Content provided by Formedix | 01-Aug-2023 | White Paper

When it comes to efficient clinical study build, content is king. Most importantly: metadata content. In this blog, we explore the role of metadata in...

Related suppliers

Follow us


View more